Jacobs Levy Equity Management’s Adverum Biotechnologies ADVM Stock Holding History

Jacobs Levy Equity Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-55,621	Closed	-$528K	–	939
2022 Q3	$528K	Sell	55,621 -3,144	-5%	-$41.3K	﹤0.01%	822
2022 Q2	$705K	Sell	58,765 -84,260	-59%	-$883K	0.01%	811
2022 Q1	$1.87M	Buy	143,025 +41,250	+41%	+$604K	0.01%	635
2021 Q4	$1.79M	Buy	101,775 +87,815	+629%	+$1.76M	0.01%	642
2021 Q3	$303K	Buy	+13,960	New	+$356K	﹤0.01%	935
2020 Q4	–	Sell	-9,654	Closed	-$994K	–	1007
2020 Q3	$994K	Sell	9,654 -1,015	-10%	-$152K	0.01%	666
2020 Q2	$2.23M	Sell	10,669 -2,561	-19%	-$454K	0.02%	514
2020 Q1	$1.29M	Buy	13,230 +786	+6%	+$91.6K	0.02%	573
2019 Q4	$1.43M	Buy	12,444 +7,144	+135%	+$630K	0.01%	612
2019 Q3	$289K	Buy	5,300 +2,120	+67%	+$239K	﹤0.01%	782
2019 Q2	$378K	Sell	3,180 -1,180	-27%	-$97.6K	0.01%	784
2019 Q1	$228K	Sell	4,360 -5,573	-56%	-$225K	﹤0.01%	877
2018 Q4	$313K	Buy	9,933 +3,904	+65%	+$159K	0.01%	806
2018 Q3	$365K	Sell	6,029 -2,246	-27%	-$126K	0.01%	835
2018 Q2	$439K	Buy	8,275 +1,286	+18%	+$77.3K	0.01%	825
2018 Q1	$405K	Sell	6,989 -1,870	-21%	-$116K	0.01%	812
2017 Q4	$310K	Sell	8,859 -310	-3%	-$10.2K	0.01%	844
2017 Q3	$335K	Buy	9,169 +970	+12%	+$26.9K	0.01%	770
2017 Q2	$205K	Buy	8,199 +5,754	+235%	+$157K	﹤0.01%	834
2017 Q1	$66K	Buy	+2,445	New	+$69.5K	﹤0.01%	883
2016 Q2	–	Sell	-2,740	Closed	-$142K	–	1145
2016 Q1	$142K	Buy	+2,740	New	+$153K	﹤0.01%	1008

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jacobs Levy Equity Management's ADVM Position: Q4 2022 in Review

Jacobs Levy Equity Management sold out of Adverum Biotechnologies (ADVM) in Q4 2022, closing a stake of 55,621 shares — an estimated $528K sold.

Jacobs Levy Equity Management first reported a position in ADVM in Q1 2016 and held it in 21 quarters. The position peaked at $2.23M in Q2 2020. 59 funds tracked by Wall St. Rank hold ADVM as of Q4 2022.

Jacobs Levy Equity Management reported no remaining Adverum Biotechnologies position as of Q4 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 55,621 Adverum Biotechnologies shares in Q4 2022, an estimated $528K.
Jacobs Levy Equity Management first reported a position in Adverum Biotechnologies in Q1 2016 and held it in 21 quarters.
Jacobs Levy Equity Management's Adverum Biotechnologies position peaked at $2.23M in Q2 2020.
59 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2022, filed 14 Feb 2023.